دورية أكاديمية
The KRAS-variant and miRNA expression in RTOG endometrial cancer clinical trials 9708 and 9905.
| العنوان: | The KRAS-variant and miRNA expression in RTOG endometrial cancer clinical trials 9708 and 9905. |
|---|---|
| المؤلفون: | Larissa J Lee, Elena Ratner, Mohamed Uduman, Kathryn Winter, Marta Boeke, Kathryn M Greven, Stephanie King, Thomas W Burke, Kelly Underhill, Harold Kim, Raleigh J Boulware, Herbert Yu, Vinita Parkash, Lingeng Lu, David Gaffney, Adam P Dicker, Joanne Weidhaas |
| المصدر: | PLoS ONE, Vol 9, Iss 4, p e94167 (2014) |
| بيانات النشر: | Public Library of Science (PLoS), 2014. |
| سنة النشر: | 2014 |
| المجموعة: | LCC:Medicine LCC:Science |
| مصطلحات موضوعية: | Medicine, Science |
| الوصف: | ObjectiveTo explore the association of a functional germline variant in the 3'-UTR of KRAS with endometrial cancer risk, as well as the association of microRNA (miRNA) signatures and the KRAS-variant with clinical characteristics and survival outcomes in two prospective RTOG endometrial cancer trials.Methods/materialsThe association of the KRAS-variant with endometrial cancer risk was evaluated by case-control analysis of 467 women with type 1 or 2 endometrial cancer and 582 age-matched controls. miRNA and DNA were isolated for expression profiling and genotyping from tumor specimens of 46 women with type 1 endometrial cancer enrolled in RTOG trials 9708 and 9905. miRNA expression levels and KRAS-variant genotype were correlated with patient and tumor characteristics, and survival outcomes were evaluated by variant allele type.ResultsThe KRAS-variant was not significantly associated with overall endometrial cancer risk (14% controls and 17% type 1 cancers), although was enriched in type 2 endometrial cancers (24%, p = 0.2). In the combined analysis of RTOG 9708/9905, miRNA expression differed by age, presence of lymphovascular invasion and KRAS-variant status. Overall survival rates at 3 years for patients with the variant and wild-type alleles were 100% and 77% (HR 0.3, p = 0.24), respectively, favoring the variant.ConclusionsThe KRAS-variant may be a genetic marker of risk for type 2 endometrial cancers. In addition, tumor miRNA expression appears to be associated with patient age, lymphovascular invasion and the KRAS-variant, supporting the hypothesis that altered tumor biology can be measured by miRNA expression, and that the KRAS-variant likely impacts endometrial tumor biology. |
| نوع الوثيقة: | article |
| وصف الملف: | electronic resource |
| اللغة: | English |
| تدمد: | 1932-6203 |
| Relation: | https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/24732316/?tool=EBI; https://doaj.org/toc/1932-6203 |
| DOI: | 10.1371/journal.pone.0094167 |
| URL الوصول: | https://doaj.org/article/8813e1cb07004ce2a0b7f0b8c9ae27fa |
| رقم الأكسشن: | edsdoj.8813e1cb07004ce2a0b7f0b8c9ae27fa |
| قاعدة البيانات: | Directory of Open Access Journals |
Full Text Finder | تدمد: | 19326203 |
|---|---|
| DOI: | 10.1371/journal.pone.0094167 |